Intellia Therapeutics Inc

-0.23 (-0.34%)
Products, Regulatory, Other Pre-Announcement

Intellia Presents Data Showing Persistent In Vivo Editing And Durability Of Effect Following Crispr/Cas9-Based Treatment

Published: 09/29/2020 13:54 GMT
Intellia Therapeutics Inc (NTLA) - Intellia Therapeutics Presents New Preclinical Data Showing Persistent in Vivo Editing and Durability of Effect Following Crispr/cas9-based Treatment.
Intellia Therapeutics - Anticipates Submitting Investigational New Drug Application Or Ind-equivalent for Ntla-2002 in H2 of 2021.
Intellia Therapeutics Inc - Co's First Systemic Treatment (ntla-2001) Expected to Enter Clinic by Year-end.
Intellia Therapeutics Inc - Expects to Dose First Attr Patient by Year-end With Ntla-2001.
Intellia - New Data Show Persistent in Vivo Liver Gene Knockouts & Corresponding Protein Reduction Achieved Employing Intellia's Modular Platform.